What's New in Canine Lymphoma?
1.0 CE Credit Hour / Craig Clifford, DVM, DACVIM
Craig Clifford, DVM, DACVIM
Medical Oncologist
BluePearl Malvern
Dr. Craig Clifford graduated from Mississippi State University College of Veterinary Medicine and received an MS in Animal Science /Virology from the University of Delaware. After completing an internship and a medical oncology residency at the University of Pennsylvania, he became a diplomate of the American College of Veterinary Internal Medicine (Oncology) in 2003. He is a medical oncologist at BluePearl Malvern.
He is active in clinical research within a referral setting and serves as an advisory board member with industry and non-profit foundations. He has authored/co-authored over 70 papers and book chapters and is a frequent lecturer at major veterinary meetings in the USA and abroad.
Dr. Clifford is a member of the Mars Veterinary Health Oncology Advisory Board, has served on many VCS and ACVIM committees, is a member of the Oncology Pathology Working Group, and was an Examiner for the Australian Scientist’s Oncology Specialty Exam.
Program Description:
This lecture will discuss the importance of phenotyping and how this affect not only prognosis but therapy for canine lymphoma as well the use of Laverdia and where we see this drug fitting in.
Learning Objectives
- Immunophenotyping is essential for both prognosis and therapy
- Flow cytometry, immunohistochemistry, and immunocytochemistry are all immunophenotyping tests.
- Indolent lymphoma is a less aggressive form of lymphoma often requiring no therapy.
This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.
This activity is sponsored by Volition Veterinary
